Sepracor settles US Xopenex patent suit with Teva
This article was originally published in Scrip
Executive Summary
Sepracorhas settled a patent infringement suit withBarr Laboratories, now a part ofTeva Pharmaceutical Industries, in connection with the generics firm's ANDA for the short acting beta-agonist Xopenex (levalbuterol HCl inhalation solution), thus permitting Teva to launch generic levalbuterol in the US on February 17th, 2013, under a non-exclusive licence. Sepracor and Teva will ask the US District Court for the District of Delaware to dismiss their litigation.